144 related articles for article (PubMed ID: 20413726)
21. Regional differences in capillary density, perfusion rate, and P-glycoprotein activity: a quantitative analysis of regional drug exposure in the brain.
Zhao R; Pollack GM
Biochem Pharmacol; 2009 Oct; 78(8):1052-9. PubMed ID: 19523457
[TBL] [Abstract][Full Text] [Related]
22. Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice.
Chu C; Abbara C; Noël-Hudson MS; Thomas-Bourgneuf L; Gonin P; Farinotti R; Bonhomme-Faivre L
Biochem Pharmacol; 2009 May; 77(10):1629-34. PubMed ID: 19426700
[TBL] [Abstract][Full Text] [Related]
23. Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance.
Agarwal S; Elmquist WF
Mol Pharm; 2012 Mar; 9(3):678-84. PubMed ID: 22335402
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo evaluation of the effects of piperine on P-gp function and expression.
Han Y; Chin Tan TM; Lim LY
Toxicol Appl Pharmacol; 2008 Aug; 230(3):283-9. PubMed ID: 18417181
[TBL] [Abstract][Full Text] [Related]
25. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672.
Elsby R; Gillen M; Butters C; Imisson G; Sharma P; Smith V; Surry DD
Drug Metab Dispos; 2011 Feb; 39(2):275-82. PubMed ID: 21075975
[TBL] [Abstract][Full Text] [Related]
26. P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats.
Kamath AV; Chong S; Chang M; Marathe PH
Cancer Chemother Pharmacol; 2005 Feb; 55(2):110-6. PubMed ID: 15338193
[TBL] [Abstract][Full Text] [Related]
27. A combined cell based approach to identify P-glycoprotein substrates and inhibitors in a single assay.
Balimane PV; Chong S
Int J Pharm; 2005 Sep; 301(1-2):80-8. PubMed ID: 16023314
[TBL] [Abstract][Full Text] [Related]
28. 20(S)-ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: a case for herb-drug interactions.
Zhang J; Zhou F; Wu X; Gu Y; Ai H; Zheng Y; Li Y; Zhang X; Hao G; Sun J; Peng Y; Wang G
Drug Metab Dispos; 2010 Dec; 38(12):2179-87. PubMed ID: 20837659
[TBL] [Abstract][Full Text] [Related]
29. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.
Hu S; Chen Z; Franke R; Orwick S; Zhao M; Rudek MA; Sparreboom A; Baker SD
Clin Cancer Res; 2009 Oct; 15(19):6062-9. PubMed ID: 19773380
[TBL] [Abstract][Full Text] [Related]
30. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
Hsiao P; Bui T; Ho RJ; Unadkat JD
Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117
[TBL] [Abstract][Full Text] [Related]
31. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.
Smit JW; Huisman MT; van Tellingen O; Wiltshire HR; Schinkel AH
J Clin Invest; 1999 Nov; 104(10):1441-7. PubMed ID: 10562306
[TBL] [Abstract][Full Text] [Related]
32. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation.
Lagas JS; van Waterschoot RA; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Mol Cancer Ther; 2010 Feb; 9(2):319-26. PubMed ID: 20103600
[TBL] [Abstract][Full Text] [Related]
33. P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration.
Iusuf D; Teunissen SF; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
J Pharmacol Exp Ther; 2011 Jun; 337(3):710-7. PubMed ID: 21378205
[TBL] [Abstract][Full Text] [Related]
34. In vitro to in vivo evidence of the inhibitor characteristics of Schisandra lignans toward P-glycoprotein.
Liang Y; Zhou Y; Zhang J; Liu Y; Guan T; Wang Y; Xing L; Rao T; Zhou L; Hao K; Xie L; Wang GJ
Phytomedicine; 2013 Aug; 20(11):1030-8. PubMed ID: 23731657
[TBL] [Abstract][Full Text] [Related]
35. P-glycoprotein mediated efflux in Caco-2 cell monolayers: the influence of herbals on digoxin transport.
Oga EF; Sekine S; Shitara Y; Horie T
J Ethnopharmacol; 2012 Dec; 144(3):612-7. PubMed ID: 23064285
[TBL] [Abstract][Full Text] [Related]
36. Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux.
Neuhoff S; Yeo KR; Barter Z; Jamei M; Turner DB; Rostami-Hodjegan A
J Pharm Sci; 2013 Sep; 102(9):3145-60. PubMed ID: 23703021
[TBL] [Abstract][Full Text] [Related]
37. In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes.
Schmitt U; Kirschbaum KM; Poller B; Kusch-Poddar M; Drewe J; Hiemke C; Gutmann H
Pharmacol Biochem Behav; 2012 Aug; 102(2):312-20. PubMed ID: 22525746
[TBL] [Abstract][Full Text] [Related]
38. Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
Bundgaard C; Jensen CJ; Garmer M
Drug Metab Dispos; 2012 Mar; 40(3):461-6. PubMed ID: 22112383
[TBL] [Abstract][Full Text] [Related]
39. Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys.
Uchida Y; Wakayama K; Ohtsuki S; Chiba M; Ohe T; Ishii Y; Terasaki T
J Pharmacol Exp Ther; 2014 Sep; 350(3):578-88. PubMed ID: 24947467
[TBL] [Abstract][Full Text] [Related]
40. The anthelminthic agent albendazole does not interact with p-glycoprotein.
Merino G; Alvarez AI; Prieto JG; Kim RB
Drug Metab Dispos; 2002 Apr; 30(4):365-9. PubMed ID: 11901088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
